Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

The company’s investigational treatment for obesity and type 2 diabetes, MariTide, is of particular interest, with Phase 2 trial data expected in the second half of 2025. Analysts from Goldman Sachs ...

The stock is down by over 11% in the past 12 months. The decline could be attributed to its leading weight loss candidate, MariTide, falling short of expectations in a mid-stage trial. Despite ...

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...

The market recently punished Amgen's shares after its leading weight loss candidate, MariTide, failed to impress in a mid-stage study. The stock has rebounded somewhat since that debacle ...